Clozapine: (Contraindicated) Avoid concomitant use of ketoconazole and clozapine due to an elevated threat for buy dihydrocodeine online uk torsade de pointes (TdP) and QT/QTc prolongation. Moreover, concomitant use may improve the publicity of clozapine, thereby additional rising the danger for hostile occasions. Clozapine is a CYP3A substrate and ketoconazole is a robust CYP3A inhibitor.
Loperamide: (Contraindicated) Concomitant use of loperamide and ketoconazole is contraindicated on account of an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Concomitant use may additionally improve loperamide exposure and the danger for different loperamide-related adversarial results; loperamide is a CYP3A and P-gp substrate and ketoconazole is a strong CYP3A and P-gp inhibitor. Coadministration with another sturdy CYP3A4 and P-gp inhibitor increased loperamide publicity by 3.8-fold.
Tamoxifen: (Reasonable) Concomitant use of tamoxifen and ciprofloxacin might increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, corresponding to avoidance, electrolyte monitoring and repletion, and ECG monitoring, particularly in patients with additional danger components for TdP.
Anagrelide: (Moderate) Anagrelide has been shown to inhibit CYP1A2. In principle, coadministration of anagrelide with substrates of CYP1A2, together with caffeine, could lead to will increase in the serum concentrations of caffeine and, thus, adversarial results. (Average) Anagrelide is partially metabolized by CYP1A2. Coadministration of anagrelide with medicine that induce CYP1A2, resembling barbiturates, may theoretically enhance the elimination of anagrelide and decrease the efficacy of anagrelide.